Literature DB >> 12391189

T cell requirement for development of chronic ulcerative dermatitis in E- and P-selectin-deficient mice.

S Bradley Forlow1, E James White, Kennard L Thomas, Gregory J Bagby, Patricia L Foley, Klaus Ley.   

Abstract

C57BL/6 mice deficient in E- and P-selectin (E(-/-)P(-/-)) kept under specific pathogen-free barrier conditions have high circulating neutrophil counts and develop hypercellular cervical lymph nodes with substantial plasma cell infiltrates, severe ulcerative dermatitis, conjunctivitis, and lung pathology, which eventually lead to premature death. To test the hypothesis that the pathology in E(-/-)P(-/-) mice may be caused by dysfunctional lymphocyte activity, we crossed E(-/-)P(-/-) mice with recombination activation gene (Rag)-1(-/-) mice to generate E(-/-)P(-/-)Rag-1(-/-) mice lacking mature T and B lymphocytes. E(-/-)P(-/-)Rag-1(-/-) mice had circulating neutrophil counts and plasma G-CSF levels similar to E(-/-)P(-/-) mice. Remarkably, none of the E(-/-)P(-/-)Rag-1(-/-) mice developed conjunctivitis or ulcerative dermatitis typical of E(-/-)P(-/-) mice. These mice were overall healthier in appearance than E(-/-)P(-/-) mice, and histopathologic changes in the lung were reduced. Cervical lymph nodes in E(-/-)P(-/-)Rag-1(-/-) mice were much smaller than those of E(-/-)P(-/-) mice, containing few mononuclear cells and no plasma cells. These data show that the severe disease phenotype of E(-/-)P(-/-) mice depends on lymphocyte function. We conclude that a dysregulated immune response in E(-/-)P(-/-) mice causes disease development, but is not necessary for elevated neutrophil counts.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12391189     DOI: 10.4049/jimmunol.169.9.4797

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Primary follicular dystrophy with scarring dermatitis in C57BL/6 mouse substrains resembles central centrifugal cicatricial alopecia in humans.

Authors:  J P Sundberg; D Taylor; G Lorch; J Miller; K A Silva; B A Sundberg; D Roopenian; L Sperling; D Ong; L E King; H Everts
Journal:  Vet Pathol       Date:  2010-09-22       Impact factor: 2.221

2.  Phospholipase cbeta is critical for T cell chemotaxis.

Authors:  Tami L Bach; Qing-Min Chen; Wesley T Kerr; Yanfeng Wang; Lurong Lian; John K Choi; Dianqing Wu; Marcelo G Kazanietz; Gary A Koretzky; Sally Zigmond; Charles S Abrams
Journal:  J Immunol       Date:  2007-08-15       Impact factor: 5.422

3.  Association between hair-induced oronasal inflammation and ulcerative dermatitis in C57BL/6 mice.

Authors:  Sandra M Duarte-Vogel; Gregory W Lawson
Journal:  Comp Med       Date:  2011-02       Impact factor: 0.982

4.  T-lineage cells require the thymus but not VDJ recombination to produce IL-17A and regulate granulopoiesis in vivo.

Authors:  Emily Smith; Sibylle von Vietinghoff; Matthew A Stark; Alexander Zarbock; John M Sanders; Amanda Duley; Jesus Rivera-Nieves; Timothy P Bender; Klaus Ley
Journal:  J Immunol       Date:  2009-11-01       Impact factor: 5.422

5.  Comparison of 3 Topical Treatments against Ulcerative Dermatitis in Mice with a C57BL/6 Background.

Authors:  Carmen R Michaud; Jing Qin; William R Elkins; Alfonso S Gozalo
Journal:  Comp Med       Date:  2016-04       Impact factor: 0.982

6.  Palatability and treatment efficacy of various ibuprofen formulations in C57BL/6 mice with ulcerative dermatitis.

Authors:  Paula C Ezell; Luis Papa; Gregory W Lawson
Journal:  J Am Assoc Lab Anim Sci       Date:  2012       Impact factor: 1.232

Review 7.  Systematic Literature Review of Risk Factors and Treatments for Ulcerative Dermatitis in C57BL/6 Mice.

Authors:  Jennifer L Sargent; Nathan J Koewler; Helen E Diggs
Journal:  Comp Med       Date:  2015-12       Impact factor: 0.982

8.  A "Pedi" Cures All: Toenail Trimming and the Treatment of Ulcerative Dermatitis in Mice.

Authors:  Sean C Adams; Joseph P Garner; Stephen A Felt; Jerome T Geronimo; David K Chu
Journal:  PLoS One       Date:  2016-01-06       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.